SCHEMBL16747649

SCHEMBL16747649

CN(Cc1cc(N)cc(F)c1O[C@H]1CCOC1)C(=O)OCc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 4/20 0.38
PDE4A P27815 3/20 0.38
PDE4B Q07343 3/20 0.38
PDE4C Q08493 3/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
S1PR3 Q99500 1/20 0.36
HTR2A P28223 1/20 0.35
MAPK1 P28482 1/20 0.35
CTSL P07711 2/20 0.35
FFAR1 O14842 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
RORC P51449 2/20 0.34
HDAC1 Q13547 1/20 0.34
GRM4 Q14833 1/20 0.34
MLNR O43193 1/20 0.33
ABCB11 O95342 1/20 0.33
LMNA P02545 1/20 0.33
CTSD P07339 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16744732 1.00 PDE4D (0.38) PDE4DPDE4APDE4BPDE4CPTGDR2
SCHEMBL16737900 0.76 CTSL (0.32) PDE4DPDE4APDE4BPDE4CPTGDR2
SCHEMBL16737797 0.76 CTSL (0.32) PDE4DPDE4APDE4BPDE4CPTGDR2
SCHEMBL16737939 0.76 CTSL (0.32) PDE4DPDE4APDE4BPDE4CPTGDR2
SCHEMBL16737879 0.76 CTSL (0.32) PDE4DPDE4APDE4BPDE4CPTGDR2
SCHEMBL16737899 0.76 CTSL (0.32) PDE4DPDE4APDE4BPDE4CPTGDR2
SCHEMBL16747639 0.75 PTGDR2 (0.40) PTGDR2HTR2AHDAC1LMNA
SCHEMBL16737839 0.71 KMT2A (0.44) LMNA
SCHEMBL16737861 0.71 PTGDR2 (0.35) PTGDR2MAPK1RORC
SCHEMBL16737859 0.71 PTGDR2 (0.35) PTGDR2MAPK1RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9174974-B2 Macrocyclic factor VIIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-03 US disclosed
US-20150148313-A1 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148313-A1 MACROCYCLIC FACTOR VIIA INHIBITORS F7, F12, F5 PDE4D 2115/4885PDE4A 2184/4885PDE4B 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.